Control Bionics Ltd (CBL) - Net Assets
Based on the latest financial reports, Control Bionics Ltd (CBL) has net assets worth AU$6.31 Million AUD (≈ $4.47 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$9.05 Million ≈ $6.40 Million USD) and total liabilities (AU$2.73 Million ≈ $1.93 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CBL capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$6.31 Million |
| % of Total Assets | 69.77% |
| Annual Growth Rate | -24.96% |
| 5-Year Change | -47.06% |
| 10-Year Change | -97.76% |
| Growth Volatility | 96.82 |
Control Bionics Ltd - Net Assets Trend (2014–2025)
This chart illustrates how Control Bionics Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Control Bionics Ltd market cap and net worth.
Annual Net Assets for Control Bionics Ltd (2014–2025)
The table below shows the annual net assets of Control Bionics Ltd from 2014 to 2025. Also explore net asset momentum of Control Bionics Ltd to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | AU$6.31 Million ≈ $4.47 Million |
+14.60% |
| 2024-12-31 | AU$5.51 Million ≈ $3.90 Million |
-12.11% |
| 2023-12-31 | AU$6.27 Million ≈ $4.43 Million |
-11.92% |
| 2022-12-31 | AU$7.12 Million ≈ $5.04 Million |
-40.32% |
| 2021-12-31 | AU$11.92 Million ≈ $8.44 Million |
-30.53% |
| 2020-12-31 | AU$17.16 Million ≈ $12.14 Million |
-14.72% |
| 2019-12-31 | AU$20.13 Million ≈ $14.24 Million |
+298.26% |
| 2018-12-31 | AU$5.05 Million ≈ $3.58 Million |
-17.02% |
| 2017-12-31 | AU$6.09 Million ≈ $4.31 Million |
-97.84% |
| 2016-12-31 | AU$281.41 Million ≈ $199.11 Million |
+54.91% |
| 2015-12-31 | AU$181.66 Million ≈ $128.54 Million |
+22.29% |
| 2014-12-31 | AU$148.55 Million ≈ $105.11 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Control Bionics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 196.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$46.14 Million | 730.93% |
| Other Comprehensive Income | AU$2.82 Million | 44.73% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$6.31 Million | 100.00% |
Control Bionics Ltd Competitors by Market Cap
The table below lists competitors of Control Bionics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NORTH PEAK RESOURCES LTD.
F:B9TN
|
$23.84 Million |
|
BonTerra Resources Inc
V:BTR
|
$23.85 Million |
|
Radiant Innovation
TWO:3373
|
$23.85 Million |
|
Radiopharm Theranostics Limited American Depositary Shares
NASDAQ:RADX
|
$23.86 Million |
|
Plastofil -L
TA:PPIL
|
$23.81 Million |
|
Smartlink Holdings Limited
NSE:SMARTLINK
|
$23.78 Million |
|
Aguia Resources Ltd
AU:AGR
|
$23.77 Million |
|
KB Autosys Co. Ltd
KQ:024120
|
$23.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Control Bionics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,508,725 to 6,312,928, a change of 804,203 (14.6%).
- Net loss of 7,265,603 reduced equity.
- Other comprehensive income increased equity by 2,292,728.
- Other factors increased equity by 5,777,078.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-7.27 Million | -115.09% |
| Other Comprehensive Income | AU$2.29 Million | +36.32% |
| Other Changes | AU$5.78 Million | +91.51% |
| Total Change | AU$- | 14.60% |
Book Value vs Market Value Analysis
This analysis compares Control Bionics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.09x to 3.65x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | AU$0.68 | AU$0.06 | x |
| 2015-12-31 | AU$1.07 | AU$0.06 | x |
| 2016-12-31 | AU$1.26 | AU$0.06 | x |
| 2017-12-31 | AU$0.07 | AU$0.06 | x |
| 2018-12-31 | AU$0.05 | AU$0.06 | x |
| 2019-12-31 | AU$0.22 | AU$0.06 | x |
| 2020-12-31 | AU$0.19 | AU$0.06 | x |
| 2021-12-31 | AU$0.13 | AU$0.06 | x |
| 2022-12-31 | AU$0.07 | AU$0.06 | x |
| 2023-12-31 | AU$0.04 | AU$0.06 | x |
| 2024-12-31 | AU$0.02 | AU$0.06 | x |
| 2025-12-31 | AU$0.02 | AU$0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Control Bionics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -115.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -152.42%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.43x
- Recent ROE (-115.09%) is below the historical average (-45.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 18.32% | 14.29% | 0.33x | 3.84x | AU$15.12 Million |
| 2016 | 10.16% | 9.19% | 0.27x | 4.11x | AU$462.56K |
| 2017 | -15.97% | -120.74% | 0.13x | 1.04x | AU$-1.58 Million |
| 2018 | -38.22% | -247.19% | 0.14x | 1.07x | AU$-2.44 Million |
| 2019 | -5.00% | -32.44% | 0.15x | 1.02x | AU$-3.02 Million |
| 2020 | -20.69% | -86.85% | 0.22x | 1.07x | AU$-5.27 Million |
| 2021 | -51.24% | -135.72% | 0.34x | 1.13x | AU$-7.30 Million |
| 2022 | -78.78% | -99.80% | 0.65x | 1.22x | AU$-6.35 Million |
| 2023 | -94.35% | -110.52% | 0.59x | 1.44x | AU$-6.54 Million |
| 2024 | -110.89% | -99.41% | 0.75x | 1.49x | AU$-6.66 Million |
| 2025 | -115.09% | -152.42% | 0.53x | 1.43x | AU$-7.90 Million |
Industry Comparison
This section compares Control Bionics Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $43,889,687
- Average return on equity (ROE) among peers: -44.83%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Control Bionics Ltd (CBL) | AU$6.31 Million | 18.32% | 0.43x | $23.82 Million |
| 4DMEDICAL Ltd (4DX) | $3.78 Million | -104.20% | 0.44x | $1.75 Billion |
| Adherium Ltd (ADR) | $-4.76 Million | 0.00% | 0.00x | $3.18 Million |
| Aroa Biosurgery Ltd (ARX) | $1.81 Million | 0.00% | 6.66x | $130.04 Million |
| Atomo Diagnostics Ltd (AT1) | $10.08 Million | -67.90% | 0.13x | $11.49 Million |
| Avita Medical Inc (AVH) | $3.98 Million | -125.89% | 0.98x | $188.51 Million |
| Anteris Technologies Global Corp (AVR) | $13.64 Million | -10.42% | 0.08x | $809.31 Million |
| Cardiex Ltd (CDX) | $1.88 Million | -105.36% | 1.22x | $13.23 Million |
| Compumedics Ltd (CMP) | $9.21 Million | -30.70% | 1.16x | $33.22 Million |
| Cochlear Ltd (COH) | $355.39 Million | 41.04% | 1.46x | $6.20 Billion |
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more